Skip to main content Accessibility help
×
×
Home
  • Print publication year: 2015
  • Online publication date: April 2015

Chapter 54 - Cancer genetics

from Section 7 - Gynecological oncology
Recommend this book

Email your librarian or administrator to recommend adding this book to your organisation's collection.

Clinical Gynecology
  • Online ISBN: 9781139628938
  • Book DOI: https://doi.org/10.1017/CBO9781139628938
Please enter your name
Please enter a valid email address
Who would you like to send this to *
×

References

1. KnudsonAG II. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971;68:820–823.
2. KnudsonAG. Two genetic hits (more or less) to cancer. Nat Rev Cancer 2001;1:157–162.
3. FutrealPA, CoinL, MarshallM, et al. A census of human cancer genes. Nat Rev Cancer 2004;4:177–183.
4. GrowdonWB, RousselBN, ScialabbaVL, et al. Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin. Gynecol Oncol 2011;121:212–217.
5. VogelsteinB, KinzlerKW. Cancer genes and the pathways they control. Nat Med 2004;10:789–799.
6. SherrCJ. Principles of tumor suppression. Cell 2004;116:235–246.
7. PharoahPD, DayNE, DuffyS, EastonDF, PonderBA. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer 1997;71:800–809.
8. StrattonJF, PharoahP, SmithSK, et al. A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol 1998;105:493–499.
9. KingMC, MarksJH, MandellJB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643–646.
10. LiuG, YangD, SunY, et al. Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer. Pharmacogenomics 2012;13:1523–1535.
11. ArasonA, JonasdottirA, BarkardottirRB, et al. A population study of mutations and LOH at breast cancer gene loci in tumours from sister pairs: two recurrent mutations seem to account for all BRCA1/BRCA2 linked breast cancer in Iceland. J Med Genet 1998;35:446–449.
12. NarodSA. Modifiers of risk of hereditary breast and ovarian cancer. Nat Rev Cancer 2002;2:113–123.
13. PalT, VadaparampilST. Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting. Cancer Control 2012;19:255–266.
14. RebbeckTR. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. Eur J Cancer 2002;38(Suppl 6):S15–S17.
15. ReitsmaW, de BockGH, OosterwijkJC, et al. Support of the “fallopian tube hypothesis” in a prospective series of risk-reducing salpingo-oophorectomy specimens. Eur J Cancer 2013;49:132–141.
16. LeeperK, GarciaR, SwisherE, et al. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol 2002;87:52–56.
17. BoydJ, SonodaY, FedericiMG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000;283:2260–2265.
18. BerendsMJ, WuY, SijmonsRH, et al. Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. J Clin Oncol 2003;21:4364–4370.
19. LynchHT, de la ChapelleA. Hereditary colorectal cancer. N Engl J Med 2003;348:919–932.
20. PeltomakiP. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol 2003;21:1174–1179.
21. DrakeAC, CampbellH, PorteousME, DunlopMG. The contribution of DNA mismatch repair gene defects to the burden of gynecological cancer. Int J Gynecol Cancer 2003;13:262–277.
22. LynchHT, RileyBD, WeissmanSM, et al. Hereditary nonpolyposis colorectal carcinoma (HNPCC) and HNPCC-like families: problems in diagnosis, surveillance, and management. Cancer 2004;100:53–64.
23. GemignaniML, SchlaerthAC, BogomolniyF, et al. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol 2003;90:378–381.
24. ShayestehL, LuY, KuoWL, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21:99–102.
25. HogdallEV, ChristensenL, KjaerSK, et al. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer 2003;98:66–73.
26. AunobleB, SanchesR, DidierE, BignonYJ. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer. Int J Oncol 2000;16:567–576.
27. FekiA, Irminger-FingerI. Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit Rev Oncol Hematol 2004;52:103–116.
28. KmetLM, CookLS, MaglioccoAM. A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors. Cancer 2003;97:389–404.
29. PenningtonKP, WalshT, LeeM, et al. BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma. Cancer 2013;119:332–338.
30. MarshDJ, CoulonV, LunettaKL, et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan–Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet 1998;7:507–515.
31. FrankeTF, HornikCP, SegevL, et al. PI3K/AKT and apoptosis: size matters. Oncogene 2003;22:8983–8998.
32. SansalI, SellersWR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004;22:2954–2963.
33. KuroseK, ZhouXP, ArakiT, et al. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin Dl expression, in primary epithelial ovarian carcinomas. Am J Pathol 2001;158:2097–2106.
34. MackayHJ, GallingerS, TsaoMS, et al. Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: results from studies of the NCIC Clinical Trials Group (NCIC CTG). Eur J Cancer 2010;46:1365–1373.
35. LynchMA, NakashimaR, SongH, et al. Mutational analysis of the transforming growth factor beta receptor type II gene in human ovarian carcinoma. Cancer Res 1998;58:4227–4232.
36. PekarskyY, PalamarchukA, HuebnerK, CroceCM. FHIT as tumor suppressor: mechanisms and therapeutic opportunities. Cancer Biol Ther 2002;1:232–236.
37. SalvesenHB, DasS, AkslenLA. Loss of nuclear pi 6 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. Clin Cancer Res 2000;6:153–159.